Tango Therapeutics is a biotech company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients. Startup focuses on three areas of drug development which includes: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion.
Tango Therapeutics, Inc.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/tango-therapeutics” connections=”true” suffix=””]
Tango Therapeutics has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than todays targeted therapies, and extend the benefit of available immuno-oncology agents.
Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures.